News | November 17, 2025
Lupin launches long-acting Risperidone in US
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
Quest Diagnostics’ blood-based test panels demonstrate confirmatory accuracy, potentially reducing the need for PET imaging
Sodium Zirconium Cyclosilicate powder for oral suspension 5g (Lokelma) is indicated for the treatment of hyperkalaemia in adult patients
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
Paroxetine Extended-Release Tablets USP, 25 mg and 37.5 mg, are indicated for the treatment of major depressive disorder
Ultra-high purity surfactant for biologics and parenteral drug formulations
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
This is Lupin's first product using proprietary Nanomi's technology and has a 180-day CGT exclusivity
Subscribe To Our Newsletter & Stay Updated
